Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
Status:
Recruiting
Trial end date:
2027-07-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of 2 doses of crizanlizumab
(5.0 mg/kg and 7.5 mg/kg) versus placebo in adolescent and adult sickle cell disease (SCD)
patients with history of vaso-occlusive crisis (VOC) leading to healthcare visit.